{"id":44967,"date":"2025-10-08T23:50:01","date_gmt":"2025-10-08T21:50:01","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2025\/10\/08\/car-ving-a-path-metalloprotease-engineered-car-t-cells-tunnel-through-solid-tumors\/"},"modified":"2025-10-08T23:50:01","modified_gmt":"2025-10-08T21:50:01","slug":"car-ving-a-path-metalloprotease-engineered-car-t-cells-tunnel-through-solid-tumors","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2025\/10\/08\/car-ving-a-path-metalloprotease-engineered-car-t-cells-tunnel-through-solid-tumors\/","title":{"rendered":"CAR-ving a Path: Metalloprotease-Engineered CAR T Cells Tunnel through Solid Tumors"},"content":{"rendered":"<div>\n<p><b>Cancer Immunol Res<\/b>. 2025 Oct 8:OF1-OF2. doi: 10.1158\/2326-6066.CIR-25-1097. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Overcoming the physical barriers of the tumor microenvironment remains a major obstacle for chimeric antigen receptor (CAR) T-cell therapy in solid tumors. In this issue, Van Pelt and colleagues show that engineering GD2-targeting CAR T cells to express matrix metalloproteinase 7 and osteopontin-b enhances their ability to infiltrate tumors rich in extracellular matrix. These modifications improve functionality in preclinical models without increasing off-target toxicity. The findings highlight a promising strategy to design CAR T cells with extracellular matrix-remodeling capabilities. See related article by Van Pelt et al., p. XX .<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41059961\/?utm_source=SimplePie&amp;utm_medium=rss&amp;utm_content=101614637&amp;ff=20251008175001&amp;v=2.18.0.post9+e462414\">41059961<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1158\/2326-6066.CIR-25-1097\">10.1158\/2326-6066.CIR-25-1097<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Cancer Immunol Res. 2025 Oct 8:OF1-OF2. doi: 10.1158\/2326-6066.CIR-25-1097. Online ahead of print. ABSTRACT Overcoming the physical barriers of the tumor microenvironment remains a major obstacle for chimeric antigen receptor (CAR) T-cell therapy in solid tumors. In this issue, Van Pelt and colleagues show that engineering GD2-targeting CAR T cells to express matrix metalloproteinase 7 and &#8230; <a title=\"CAR-ving a Path: Metalloprotease-Engineered CAR T Cells Tunnel through Solid Tumors\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/10\/08\/car-ving-a-path-metalloprotease-engineered-car-t-cells-tunnel-through-solid-tumors\/\" aria-label=\"Read more about CAR-ving a Path: Metalloprotease-Engineered CAR T Cells Tunnel through Solid Tumors\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[55,42],"tags":[],"class_list":["post-44967","post","type-post","status-publish","format-standard","hentry","category-cancer-immunology-reserch","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/44967","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=44967"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/44967\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=44967"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=44967"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=44967"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}